Advanced Medical Solutions Group announced its unaudited interim results for the six months ended 30 June 2026 Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2026. Group revenue increased by 4% to £115.5 million and by 3% at […]
Hansa Biopharma announces the first commercial kidney transplant patient treated with Idefirix in Australia Hansa Biopharma AB, announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). AC Immune announces positive preliminary Phase 1 data […]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]
Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026. Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]
Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]
